An evolutionarily conserved PTEN-C/EBPalpha-CTNNA1 axis controls myeloid development and transformation

Area of Science:

• Molecular Biology
• Cancer Genetics
• Cell Signaling

Background:

• Loss of function in tumor suppressor genes like PTEN, CEBPAlpha, and CTNNA1 is crucial in leukemogenesis.
• The genetic interactions between these tumor suppressor genes in leukemia remain largely unexplored.

Purpose of the Study:

• To elucidate the molecular mechanisms and genetic interactions between PTEN, CEBPAlpha, and CTNNA1 in leukemogenesis.
• To identify a novel therapeutic strategy targeting leukemia stem cells (LICs).

Main Methods:

• Investigated the PTEN-mammalian target of rapamycin (mTOR) signaling pathway.
• Analyzed the binding of C/EBPalpha isoforms to the CTNNA1 promoter.
• Utilized mouse and zebrafish models to study the in vivo effects of Pten loss.
• Performed mutational analysis on PTEN and CEBPA in primary LICs.

Main Results:

• PTEN-mTOR signaling dictates the ratio of p42 C/EBPalpha to p30 C/EBPalpha, influencing CTNNA1 expression.
• The p30 C/EBPalpha isoform recruits Polycomb Repressive Complex 2, suppressing CTNNA1 via H3K27me3.
• The p42 C/EBPalpha isoform promotes CTNNA1 expression via H3K4me3 modification.
• Loss of Pten in vivo resulted in myelodysplasia and reduced C/EBPalpha and alpha-catenin.
• Mutations in PTEN or CEBPA were found in LICs with low CTNNA1 expression.

Conclusions:

• Identified a novel, evolutionarily conserved PTEN-C/EBPalpha-CTNNA1 molecular pathway critical for leukemogenesis.
• This pathway regulates CTNNA1 expression through differential binding of C/EBPalpha isoforms and epigenetic modifications.
• The pathway represents a potential therapeutic target for eradicating LICs characterized by low CTNNA1 expression.